Haematology · Oncology
BALL Score for Relapsed/Refractory CLL calculator
Enter the published formula inputs below to calculate and interpret this score.
Clinical inputs
Result
Anyone can run this calculator. Sign in to save, favourite, or send the result.
0
BALL low risk (0–1)
Band: BALL low risk (0–1)
Interpretation. BALL low risk (0–1)
Suggested management. 0–1 adverse factors: the low-risk group, with the best overall survival in the derivation cohort on targeted agents.
BALL Score for Relapsed/Refractory CLL: 0 — BALL low risk (0–1). Interpretation: BALL low risk (0–1) What to do: 0–1 adverse factors: the low-risk group, with the best overall survival in the derivation cohort on targeted agents. Inputs: Beta-2 microglobulin (β2M): false; Lactate dehydrogenase (LDH): false; Anemia: false; Time since last therapy: false Source: Soumerai JD et al. Risk model for relapsed chronic lymphocytic leukaemia treated with targeted agents (BALL). Lancet Haematol. DOI: 10.1016/S2352-3026(19)30052-2. PMID: 31109827. One point each: serum β2-microglobulin ≥5 mg/dL (unit as printed in the abstract and Table 2), haemoglobin <110 g/L in women or <120 g/L in men, LDH above the upper limit of normal, and less than 24 months from the start of the last therapy. Risk groups: 0–1 low, 2–3 intermediate, 4 high. Validated with ibrutinib by Molica S et al. Leuk Res 2020 (PMID 32562875). (2019)
Ruqelo is AI and can make mistakes. Check important information.
Clinical inputs
- Beta-2 microglobulin (β2M)
- Lactate dehydrogenase (LDH)
- Anemia
- Time since last therapy
Primary source
Soumerai JD et al. Risk model for relapsed chronic lymphocytic leukaemia treated with targeted agents (BALL). Lancet Haematol. DOI: 10.1016/S2352-3026(19)30052-2. PMID: 31109827. One point each: serum β2-microglobulin ≥5 mg/dL (unit as printed in the abstract and Table 2), haemoglobin <110 g/L in women or <120 g/L in men, LDH above the upper limit of normal, and less than 24 months from the start of the last therapy. Risk groups: 0–1 low, 2–3 intermediate, 4 high. Validated with ibrutinib by Molica S et al. Leuk Res 2020 (PMID 32562875). (2019)
View source